News

Goldman Sachs Downgrades Avantor As Shares Spiral 60% Since 2021: 'We Wrongly Assumed...'
Avantor missed Q1 sales estimates and faced multiple analyst downgrades as concerns mount over growth, competition, and product performance.
Danaher price target lowered to $240 from $260 at Goldman Sachs
Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Danaher (DHR) to $240 from $260 but keeps a Buy rating ...
Thermo Fisher price target lowered to $610 from $670 at Goldman Sachs
Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Thermo Fisher (TMO) to $610 from $670 but keeps a Buy rating on the ...
Goldman Sachs cuts Cytek Biosciences stock rating to sell
On Friday, Goldman Sachs analyst Matthew Sykes downgraded Cytek Biosciences Inc (NASDAQ:CTKB) stock rating from Buy to Sell and reduced the price target to $4.50 from the previous $7.00.
Hosted on MSN1mon
Adaptive Biotech rises as Goldman Sachs upgrades on market dynamics
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) climbed in the morning hours on Friday after Goldman Sachs upgraded the ... target from Goldman analyst Matthew Sykes. Noting that MRD patients ...
Business Insider8d
Danaher price target lowered to $240 from $260 at Goldman Sachs
Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Danaher (DHR) to $240 from $260 but keeps a Buy rating on the shares after its Q1 results. The company’s Bioprocessing ...